| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer | Chief Executive Officer | Director
3 companies
Jacob Gary S is a Chief Development Officer at OKYO, with reported holdings spanning 3 companies. Recent filings cover 5 purchases and 0 sales. Those positions are worth an estimated $401K at current prices.
Jacob Gary S's largest disclosed position is in CRDF as Director, worth about $224K. Net of sales, the recent Form 4 record there shows accumulation of 19,853 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | OKYO Okyo Pharma Ltd | Chief Executive Officer | Buy | 12,500 | $4.00 | $50,000.00 | New | -32.1% | -53.2% | |
| Mar 23, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 2,370 | $10.42 | $24,689.35 | +12.1% | -22.3% | -75.7% | |
| Dec 1, 2020 | HEPA Hepion Pharmaceuticals, Inc. | Director | Buy | 12,000 | $1.66 | $19,920.00 | +20,339% | - | - | |
| May 14, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 17,483 | $1.43 | $25,000.69 | +845.0% | - | - |